Introduction：Basic information about CAS 83915-83-7|Lisinopril diydrate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Lisinopril diydrate |
|---|
| CAS Number | 83915-83-7 | Molecular Weight | 441.52 |
|---|
| Density | 1.251 g/cm3 | Boiling Point | 666.4ºC at 760 mmHg |
|---|
| Molecular Formula | C21H35N3O7 | Melting Point | 160ºC (Decomposes) |
|---|
| MSDS | USA | Flash Point | 356.9ºC |
|---|
Names
| Name | lisinopril dihydrate |
|---|
| Synonym | More Synonyms |
|---|
Lisinopril diydrate BiologicalActivity
| Description | Lisinopril Dihydrate is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.Target: ACELisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy [1, 2]. |
|---|
| Related Catalog | Signaling Pathways >>Metabolic Enzyme/Protease >>Angiotensin-converting Enzyme (ACE)Research Areas >>Cardiovascular Disease |
|---|
| References | [1]. Andujar-Sanchez, M., V. Jara-Perez, and A. Camara-Artigas, Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett, 2007. 581(18): p. 3449-54. [2]. Song, J.C. and C.M. White, Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet, 2002. 41(3): p. 207-24. |
|---|
Chemical & Physical Properties
| Density | 1.251 g/cm3 |
|---|
| Boiling Point | 666.4ºC at 760 mmHg |
|---|
| Melting Point | 160ºC (Decomposes) |
|---|
| Molecular Formula | C21H35N3O7 |
|---|
| Molecular Weight | 441.52 |
|---|
| Flash Point | 356.9ºC |
|---|
| PSA | 132.96000 |
|---|
| LogP | 2.26430 |
|---|
| Index of Refraction | -45 ° (C=1, 0.25mol/L Zinc Acetate Buffer) |
|---|
| InChIKey | CZRQXSDBMCMPNJ-ZUIPZQNBSA-N |
|---|
| SMILES | NCCCCC(NC(CCc1ccccc1)C(=O)O)C(=O)N1CCCC1C(=O)O.O.O |
|---|
| Storage condition | 2-8°C |
|---|
| Stability | Hygroscopic |
|---|
| Water Solubility | H2O: ≥10 mg/mL |
|---|
Toxicological Information
CHEMICAL IDENTIFICATION - RTECS NUMBER :
- TW3589990
- CHEMICAL NAME :
- L-Proline, 1-(N(sup 2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-, dihydrate, (S)-
- CAS REGISTRY NUMBER :
- 83915-83-7
- LAST UPDATED :
- 199507
- DATA ITEMS CITED :
- 2
- MOLECULAR FORMULA :
- C21-H31-N3-O5.2H2-O
- MOLECULAR WEIGHT :
- 441.59
HEALTH HAZARD DATAACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 3600 mg/kg
- SEX/DURATION :
- female 6-17 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - behavioral
- REFERENCE :
- YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,2093,1993
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 2800 mg/kg
- SEX/DURATION :
- female 15-21 day(s) after conception lactating female 21 day(s) post-birth
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
- REFERENCE :
- YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,2093,1993
|
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|
| Hazard Codes | Xi,Xn |
|---|
| Risk Phrases | R20/21/22 |
|---|
| Safety Phrases | S22-S24/25 |
|---|
| RIDADR | TW3589990 |
|---|
| WGK Germany | 3 |
|---|
| RTECS | TW3589990 |
|---|
| HS Code | 2933990090 |
|---|
Customs
| HS Code | 2933990090 |
|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|---|
Articles80
More Articles
| Isolation and characterization of a novel angiotensin-converting enzyme-inhibitory tripeptide from enzymatic hydrolysis of soft-shelled turtle (Pelodiscus sinensis) egg white: in vitro, in vivo, and in silico study. J. Agric. Food Chem. 62(50) , 12178-85, (2014) In this study, a novel angiotensin-converting enzyme (ACE)-inhibitory tripeptide (IVR) was isolated and identified from unfertilized soft-shelled turtle egg white (SSTEW). The IC50 value of IVR was me... | |
| Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310(9) , 918-29, (2013) Most patients with cardiovascular disease (CVD) do not take recommended medications long-term. The use of fixed-dose combinations (FDCs) improves adherence in several clinical areas. Previous trials o... | |
| Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension. Clin. Sci. 127(1) , 57-63, (2014) The somatic isozyme of ACE (angiotensin I-converting enzyme) comprises two distinct zinc-dependent catalytic domains with different substrate specificities for angiotensin I (cleaved selectively by th... | |
Synonyms
| L-Proline, N-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-, hydrate (1:2) |
| (S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate |
| N-[(1S)-1-Carboxy-3-phenylpropyl]-L-lysyl-L-proline dihydrate |
| MFCD08064198 |
| Lisinopril Dihydrate |
| EINECS 278-488-1 |
| Lisinopril diydrate |
| Lisinopril (dihydrate) |
